VETO Stock Analysis: Vetoquinol | PA
Drug Manufacturers - Specialty & Generic | PA, France | Market Cap: 1.029m EUR | 12M Return: 19.6% | FR0004186856 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 420K
Warnings
Tailwinds
Seasonality
Vetoquinol is a France-based veterinary pharmaceutical company that develops and sells medicines and other animal-health products for cattle, pigs, dogs and cats. Its portfolio covers areas including pain and mobility, dermatology, parasite control, antibiotics and internal medicine.
Founded in 1933 and headquartered in Lure, the company serves markets across Europe, the Americas and Asia Pacific. Its business combines products for livestock health with treatments and care products for companion animals, and it is a subsidiary of Soparfin SCA.
- Essential-product growth in companion-animal care supports revenue mix
- Livestock exposure leaves sales vulnerable to farm economics
- Currency swings and generic competition pressure margins
| Net Income: 62.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 3.62 > 1.0 |
| NWC/Revenue: 62.61% < 20% (prev 52.97%; Δ 9.64% < -1%) |
| CFO/TA 0.13 > 3% & CFO 99.9m > Net Income 62.7m |
| Net Debt (-222.8m) to EBITDA (350.6m): -0.64 < 3 |
| Current Ratio: 3.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (11.9m) vs 12m ago 0.42% < -2% |
| Gross Margin: 32.37% > 18% (prev 34.58%; Δ -2.21% > 0.5%) |
| Asset Turnover: 70.49% > 50% (prev 73.35%; Δ -2.86% > 0%) |
| Interest Coverage Ratio: 220.4 > 6 (EBIT TTM 319.0m / Interest Expense TTM 1.45m) |
| A: 0.43 (Total Current Assets 470.6m - Total Current Liabilities 140.4m) / Total Assets 770.6m |
| B: 0.04 (Retained Earnings 30.5m / Total Assets 770.6m) |
| C: 0.43 (EBIT TTM 319.0m / Avg Total Assets 748.2m) |
| D: 3.76 (Book Value of Equity 608.7m / Total Liabilities 161.8m) |
| Altman-Z'' = 9.76 = AAA |
| DSRI: 1.09 (Receivables 96.1m/89.3m, Revenue 527.4m/532.4m) |
| GMI: 1.07 (GM 34.58% / 32.37%) |
| AQI: 0.89 (AQ_t 0.27 / AQ_t-1 0.30) |
| SGI: 0.99 (Revenue 527.4m / 532.4m) |
| TATA: -0.05 (NI 62.7m - CFO 99.9m) / TA 770.6m) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 30, 2026, the stock is trading at EUR 88.50 with a total of 16,323 shares traded. Over the past week, the price has changed by +13.17%, over one month by +15.84%, over three months by +21.23% and over the past year by +19.61%.
Current recommended Stop Loss: 86.10 (which is 2.7% or 1.3 ATR below the current price).
Vetoquinol has no consensus analysts rating.
P/E Trailing = 16.2684
P/E Forward = 16.3399
P/S = 1.9509
P/B = 1.5239
P/EG = 3.7969
Revenue TTM = 527.4m EUR
EBIT TTM = 319.0m EUR
EBITDA TTM = 350.6m EUR
Long Term Debt = 156k EUR (from longTermDebt, last quarter)
Short Term Debt = 5.64m EUR (from shortTermDebt, last quarter)
Debt = 12.3m EUR (from shortLongTermDebtTotal, last quarter) (leases 12.2m already included)
Net Debt = -222.8m EUR (calculated: Debt 12.3m - CCE 235.2m)
Enterprise Value = 805.9m EUR (1.03b + Debt 12.3m - CCE 235.2m)
Interest Coverage Ratio = 220.4 (Ebit TTM 319.0m / Interest Expense TTM 1.45m)
EV/FCF = 9.26x (Enterprise Value 805.9m / FCF TTM 87.1m)
FCF Yield = 10.80% (FCF TTM 87.1m / Enterprise Value 805.9m)
FCF Margin = 16.51% (FCF TTM 87.1m / Revenue TTM 527.4m)
Net Margin = 11.90% (Net Income TTM 62.7m / Revenue TTM 527.4m)
Gross Margin = 32.37% ((Revenue TTM 527.4m - Cost of Revenue TTM 356.7m) / Revenue TTM)
Gross Margin QoQ = 58.04% (prev 7.53%)
Tobins Q-Ratio = 1.05 (Enterprise Value 805.9m / Total Assets 770.6m)
Interest Expense / Debt = 11.72% (Interest Expense 1.45m / Debt 12.3m)
Taxrate = 24.93% (19.8m / 79.5m)
NOPAT = 239.4m (EBIT 319.0m * (1 - 24.93%))
Current Ratio = 3.35 (Total Current Assets 470.6m / Total Current Liabilities 140.4m)
Debt / Equity = 0.02 (Debt 12.3m / totalStockholderEquity, last quarter 608.7m)
Debt / EBITDA = -0.64 (Net Debt -222.8m / EBITDA 350.6m)
Debt / FCF = -2.56 (Net Debt -222.8m / FCF TTM 87.1m)
Total Stockholder Equity = 585.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.38% (Net Income 62.7m / Total Assets 770.6m)
RoE = 10.71% (Net Income TTM 62.7m / Total Stockholder Equity 585.8m)
RoCE = 54.43% (EBIT 319.0m / Capital Employed (Equity 585.8m + L.T.Debt 156k))
RoIC = 39.29% (NOPAT 239.4m / Invested Capital 609.4m)
WACC = 5.42% (E(1.03b)/V(1.04b) * Re(5.38%) + D(12.3m)/V(1.04b) * Rd(11.72%) * (1-Tc(0.25)))
Discount Rate = 5.38% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.61 | Cagr: 0.19%
[DCF] Terminal Value 77.97% ; FCFF base≈74.6m ; Y1≈85.5m ; Y5≈125.8m
[DCF] Fair Price = 182.0 (EV 1.89b - Net Debt -222.8m = Equity 2.12b / Shares 11.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -50.43 | Revenue CAGR: -0.55% | SUE: N/A | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2025-12-31): EPS=5.13 | Chg30d=-1.26% | Revisions=+40% | GrowthEPS=+4.8% | GrowthRev=-2.2%
EPS next Year (2026-12-31): EPS=5.29 | Chg30d=+0.00% | Revisions=+0% | GrowthEPS=+6.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +29% (up=3, down=1)